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Abstract 
Whole slide imaging is being increasingly used in research applications and in frozen 
section, consultation and external quality assurance practice. Digital pathology when 
integrated with other digital tools such as barcoding, specimen tracking and digital dictation 
can be integrated into the histopathology workflow, from specimen accession to report sign-
out. These elements can bring about improvements in the safety, quality and efficiency of a 
histopathology department. The present paper reviews the evidence for these benefits. We 
then discuss the challenges of implementing a fully digital pathology workflow including the 
regulatory environment, validation of whole slide imaging and the evidence for the design of 
a digital pathology workstation. 
 
 
 
 
Introduction 
 
Digital pathology and whole slide imaging (WSI) - the complete digitisation of slides -  has 
the potential to transform the practice of diagnostic pathology. Radiology has been 
revolutionised by the introduction of digital imaging over the past 30 years with a resulting 
improvement in quality and safety of reporting, and innovation in the analysis and 
manipulation of radiological images. However, despite the promise of digital pathology to 
offer similar benefits, its uptake in clinical practice has been slow.  
 
Pathologists have been making diagnoses using digital images of glass microscope slides 
for many decades. Telepathology is a term coined in the 1980s to describe remote pathology 
diagnosis using digital image transmission, after the first clinical uses of telepathology in the 
late 1960s (1). Such telepathology systems are confined to live transmission of a digital 
image of part of a pathology slide, and only a small proportion of overall laboratory workload 
is examined digitally with these systems, usually where remote diagnosis is essential (such 
as intra operative frozen sections or second opinion practice). 
 
For the purposes of this article we draw a distinction between whole slide imaging (WSI) and 
digital pathology (DP). The former refers only to the high-resolution digitization and storage 
of entire glass pathology slides as digital slides (figure 1). These images can be stored, 
viewed locally or transmitted over a network for remote viewing.  Whole slide imaging 
systems are available from many vendors (2) and reviews of the technology have been 
published elsewhere (2,3). Digital pathology encompasses all the associated technologies 
that leverage digital slides to allow improvements and innovations in workflow. These include 
image and laboratory management systems, digital dictation, dashboards and workflow 
management, digital image analysis, electronic specimen labelling and tracking, and 
synoptic reporting tools. In this review article we evaluate the safety, quality and efficiency 
benefits that can be realized with a fully digital workflow and discuss the validation of digital 
slides for primary diagnosis. We then explore some of the perceived barriers to full clinical 
use of digital pathology including financial cost, regulatory factors and the acceptance of new 
ways of working amongst pathologists. 
 
 
Figure 1. A typical arrangement of slide scanners and servers required for full 
digitization of a laboratory workflow. 
 
The digital pathology workflow 
 
Digital technologies have been used in most pathology laboratories for a number of 
decades. The laboratory information management system is used at every stage of a 
specimen’s progress through the laboratory from accession to publication of a finished 
report. A variety of additional digital technologies can enhance this process thereby 
improving safety, quality and efficiency at the pre-analytical, analytical and post analytical 
phases (figure 2). 
 
 
 
 Figure 2. Benefits of a digital pathology workflow 
 
Quality, safety and efficiency benefits are present throughout the journey of a specimen from 
the clinical request through to report sign-out (EQA: external quality assurance scheme, 
MDT: multidisciplinary team meeting, IHC: immunohistochemistry, LIS: laboratory 
information system, IMS: image management system, ROI: regions of interest) 
 
 
Patient identification errors occur in up to five per cent of all cases processed in the 
pathology laboratory (4,5). Many of these errors occur at accession or during copying of 
patient details between request forms, cassettes and slides. A laboratory system employing 
end to end digital identification (for example with barcodes or radio frequency identification 
tags) would remove these manual steps to a single identification, ideally at specimen 
retrieval (i.e. at the time of biopsy or surgery). In one large study where bar coding was 
implemented for the throughput of an entire laboratory, misidentification errors were reduced 
by 62% and there was an increase in the efficiency of the pathology laboratory (6). 
Barcoding allows full laboratory tracking and provides real time information about 
specimens, assets and processes in the laboratory (7). Barcodes can also store information 
about specimen type and this data can be used to route the resulting digital slide to a certain 
pathologist or add instructions for special stains or additional levels automatically. 
 
In a totally digital pathology department the journey of a glass slide would finish in the 
laboratory after scanning. Digital slides are then available to view at any workstations. This 
saves time spent by pathologists organising, searching for and moving slides, processes that 
place demands on a pathologist’s time and attention (8).  One time and motion study of a 
digital workflow claimed opportunities to improve pathologist workflow releasing up to 13% of 
every pathologist’s time (9). This study also identified potential savings in laboratory 
technician time by removing the need to assemble and distribute trays of glass slides though 
it remains unproven if all of this time could be recouped as improved productivity in a real 
world setting. 
 
A digital workflow also creates opportunities for better management of a pathologist’s 
workload. Digital dashboards can provide information such as the number of cases to be 
reported, the progress of immunohistochemistry and special stains, and the assignment of 
specific cases to trainees. In addition the pathologist could assign cases to work lists such 
as teaching sets or multi disciplinary team meetings. These are areas where efficiency 
improvements are cited in digital radiology (10) but similar improvements have not yet been 
quantified in pathology. One published example of a digital pathology dashboard was in a 
haematopathology setting (11). The authors reported a subjective improvement in workflow 
and efficiency after the implementation of a dashboard to track, triage and direct specimens 
within the pathology department. No studies have objectively assessed the effect of such 
systems on turn around time and efficiency. 
 
The digital pathology workstation offers benefits in quality and efficiency. Digital slides can 
easily be annotated and regions of interest identified and linked to the written report. The 
report itself can be constructed using voice recognition software, a technology that has 
improved both turn around time and report accuracy in radiology (10,12). Similar results 
were seen in one analysis of this technology when implemented at a large academic 
pathology centre (13). This study showed a threefold increase in the number of reports 
signed out within 24 hours of report dictation and a reduction in transcription errors.  Finally 
most slide viewing software allows the calibrated measurement of important features such 
as distance to a surgical margin and tumour dimensions. In one comparison of digital versus 
glass slide review of prostate cancer core biopsies, a greater inter-observer agreement in 
length of affected core was found when pathologists used digital measurement (14).  
 
For the digital workflow to be beneficial to the pathology department, tight integration must 
exist between the slide scanner, IMS, LIS and the additional modules described above. Most 
WSI systems comprise a slide scanner, IMS and viewer but usually not a LIS (15). In the 
transition to a fully digital department the evaluation and costing of a suitable LIS is 
necessary to create the aforementioned integration. Additionally, the whole pathology 
laboratory system must communicate effectively with other hospital systems such as 
electronic specimen labelling and the electronic patient record. Proprietary image formats, 
LIS and IMS database design, and software for digital dictation and report creation may not 
be interchangeable between vendors and this could have an impact on the smooth 
functioning of laboratory informatics as a whole. This in turn could affect the efficiency and 
quality benefits of a fully digital workflow.  
 
Second opinion practice, collaboration and new ways of working 
Digital pathology already provides significant benefits in remote and frozen section 
diagnosis, and in second opinion practice (16–18). The use of digital pathology is particularly 
prevalent in regions such a Scandinavia and Canada where patient populations are 
dispersed over large geographical areas and specialist reporting expertise may be 
concentrated in large centres. The Eastern Quebec Telepathology Network provides the 
largest documented exposition of how digital pathology can improve healthcare provision in 
areas of dispersed populations (19,20). By providing remote macroscopic supervision, 
remote intra operative consultation, and access to expert opinions both in the primary 
diagnostic and review setting, this network reduced unnecessary two stage surgery, 
provided support for lone pathologists working in provincial hospitals and facilitated the 
recruitment and retention of both surgeons and pathologists. Transplantation histopathology 
has also benefitted from international collaboration made possible by digital pathology. A 
2012 study reported over 3000 transplant biopsies performed in Italy and reviewed as digital 
slides in the USA (21). This approach allows international expertise to be accessed in an ‘on 
call’ system where urgent results are required to decide if an organ is suitable for 
transplantation. Establishment of supra regional reporting networks of this nature has the 
potential to increase the available organ donor pool by improving access to specialist review 
(22,23). 
 
Mandatory second pathologist review prior to the issuing of a report is recommended by the 
Royal College of Pathologists in a number of situations including high grade dysplasia in 
Barrett’s Oesophagus and pT1 cancers detected in the UK bowel cancer screening program 
(24). Individual departments also have local policies for double reporting of other specimens 
(25). The time required for dual reporting can add significantly to specimen turnaround time. 
A digital pathology platform allows instant sharing of WSI in review cases as multiple 
pathologists can review the same case in parallel. With a fully digital workflow this process 
can be automated thus creating real-time quality assurance through randomly selected 
mandatory review of a proportion of all cases. Kamat et al described a system of automatic 
pre sign out second pathologist review that resulted in a decrease in the number of major 
errors in reports and empowered pathologists to proactively ask for second opinions (26). 
 
Image analysis (figure 3) 
Image analysis has long been promised as a way to remove the subjectivity and variability in 
pathology diagnosis. A fully digital workflow would mean that image analysis could be 
performed on any pathology image without the need for specific image preparation. Image 
analysis software is already widely available, and has FDA regulatory approval in the USA, 
for the quantification of nuclear markers such as oestrogen receptor or cell membrane 
markers such as HER2/neu (27). An increasing number of laboratories are incorporating 
such software into their workflow (28). An analysis of one such system demonstrated that 
semi-automated HER2 quantification could reduce inter-observer variability but raised 
concerns over the false positive rate and the potential for over-treatment (29). In this setting 
image analysis may be best placed in helping resolve equivocal HER2 measurement (30) or 
in prompting pathologists to submit these specimens for a second opinion or in-situ 
hybridisation.  
Automated image analysis has often been targeted at tasks associated with high inter- and 
intra- observer variability. Smits et al showed that the estimation of tumour cell percentage in 
lung cancer was subject to marked inter-observer variability (31).  Recent advances in 
targeted therapies for lung cancer requires accurate measurement of EGFR and ALK 
mutations in tumour tissue, and the interpretations of these tests can be altered by the 
estimated tumour cell percentage on a glass slide. Hamilton et al designed and validated an 
image analysis system that automatically measures tumour area and calculates percentage 
of tumour cells and tumour nuclei (32). This system exhibited better concordance than 
estimation by eye when compared with manually counted tumour cells. Accurate DNA 
extraction based on this method would enhance molecular testing by reducing false negative 
rates and therefore give patients access to molecular therapies that may have otherwise 
been denied. In the study hand counting of tumour cells took an estimated 100 hours per 
slide compared to 3 minutes using automated image analysis (32) , demonstrating the 
efficiencies that targeted image analysis techniques can bring to clinical practice. With more 
molecular therapies becoming available across multiple classes of cancer, accurate analysis 
of tumour mutation content is essential to ensure patients are correctly stratified to receive 
these treatments. 
Simpler diagnostic tasks such as quantifying fat in the liver, which is prone to significant 
subjectivity, can easily be performed reliably and accurately by image analysis tools, and it 
has been asserted that the time for manual evaluation of hepatic steatosis has passed (33). 
However, the widespread adoption of image analysis in diagnostic pathology faces 
significant barriers including the need for more robust standards for validation of image 
analysis, and the development of systems that facilitate pathologist workflow when 
incorporating image analysis into a clinical case.  
 Figure 3. Image analysis techniques 
A nuclear detection algorithm in use. Segmentation of nuclei and cytoplasm or tumour and 
stroma allow quantitative analysis of digital slides. Methods to analyse nuclear morphometry, 
orientation and co-localisation with other features can complement traditional 
histopathological features in providing diagnostic and prognostic information. 
 
It is unlikely that automated image analysis will completely replace the full diagnostic 
capabilities of a pathologist in the short term, but this technology could be a useful adjunct in 
the reporting process. Computer assisted safety checks could ensure that every slide in a 
case had been reviewed or that all core data items had been completed in a synoptic report. 
Image analysis techniques could be applied to present regions of interest to a pathologist 
thereby directing their expertise to specific features of a case (34,35).This could be 
particularly useful in long cases requiring prolonged periods of concentration or in cases 
where measurement of multiple foci of tumour is important such as in breast or prostate 
cancer.  It is uncertain whether pathologists would favour such systems, and their use is not 
common in digital radiology, partially due to difficulties with using the system and 
professional confidence in their outputs. 
Validation studies and examples of routine clinical use 
The last decade has seen an abundance of validation studies in digital pathology mostly 
examining concordance between a diagnosis made on glass and digital images.  A recent 
systematic review showed broad concordance in these studies but noted that study quality 
and sample size was variable (36). The digital pathology community has recognised the 
need for robust validation of whole slide imaging in the primary diagnostic setting and 
professional organisations in many countries have published guidelines for the conduct of 
validation studies (37). The College of American Pathologists (CAP) (38) and the Digital 
Pathology Association (DPA) (39) have published guidelines detailing the design and 
execution of validation studies. Both guidelines agree that studies should evaluate the entire 
WSI system in the intended practice setting and specify proper training and record keeping 
of the process. There is, however uncertainty about the optimum time between a pathologist 
viewing the same case in a glass or digital format, the so-called washout period. A recent 
study showed that a pathologist can recall 30% of previously seen cases at least 4 weeks 
after first viewing a case (40) - a timeframe longer than that in either the DPA or CAP 
guideline. The two guidelines state different minimum case numbers required for a validation 
study with the DPA requiring at least 100 cases in comparison to the CAP recommendation 
of 60 cases. These differences highlight the lack of evidence in the design of validation 
studies. However, the production of these and other guidelines provide a framework that will 
lead to better standardisation and comparability of validation studies in the future.  
The largest validation study to date involved the glass and digital slide review of over 3000 
cases (41). The study was adequately powered and followed the DPA and CAP guidelines 
on study design. Complete concordance between glass and digital slide diagnosis was seen 
in 97.7% of cases with less than 1% of non-concordance being clinically significant. A 
ground truth diagnosis for these cases was established by consensus and interestingly lay 
with the digital slide diagnosis in nine of twenty-one cases. Many validation studies comment 
on the limitations of digital pathology including difficulties viewing small objects, lack of 3 
dimensional (“z stack”) information, and possible image quality issues in some clinical areas.  
Despite many examples of successful digital pathology implementation for frozen section 
and remote consultation diagnosis there is a paucity of studies that evaluate digital 
pathology in routine clinical use. Thorstenson et al described a fully digital workflow across 
two Swedish pathology departments resulting in the digitisation of 500,000 slides (42). 
Pathologists preferentially used digital slides 38% of the time and users reported satisfaction 
with the quality of scanned images. Al-Janabi et al documented a success rate of 82% for 
primary reporting with digital slides (43). The reasons for failed digital diagnoses included 
poor scan quality, network problems, and slides that required further stains or levels leading 
to unacceptable diagnostic delay. Concordance with glass slide diagnosis was not cited as a 
reason for failure. These studies show that while primary diagnosis with digital slides is 
possible and safe, robust workflow design and reliable scanner procedures are required. 
Moreover a fully digital department requires a network infrastructure with minimal down time 
that can allow multiple users to view many different slides simultaneously. 
 
Is the fully digital pathology department cost effective? 
Pathology diagnosis with a microscope is rapid, simple and highly cost effective. Compared 
to radiology, where there are significant capital costs for scanning and viewing equipment, 
as well as ongoing maintenance and software costs, diagnosis in pathology is inexpensive. 
Pathology budgets are usually an order of magnitude smaller than radiology budgets for this 
reason. 
Implementing a fully digital pathology workflow would require significant capital outlay on 
scanners, computer servers, workstations for pathologists, and medical displays. In order to 
fully digitise the clinical work of the Histopathology (anatomic pathology) Department, an 
initial outlay of approximately £1.4 million would be required, with ongoing costs of £250,000 
per year. Given a departmental budget of approximately £9 million per year, implementing 
digital pathology would represent a significant initial outlay and ongoing cost. These costs 
must be set against a background of global economic difficulties and contracting public 
budgets, requiring pathology departments to justify increased expenditure.  
The cost must be justified in terms of its benefits on quality or income. In 2010 Henricks et 
al. described the factors affecting decisions to implement digital pathology in a laboratory 
and emphasised the need to show value in digitising slides - whether it is increased 
efficiency, reduced costs or improved quality (44). A simple cost-benefit analysis (figure 4) 
performed using data from the senior author’s institution shows the time taken for a return on 
this significant investment. This institution is a large, teaching hospital department 
comprising 45 full time equivalent consultant pathologists and 120 laboratory and 
administration staff processing 80000 specimens per year. Smaller departments may require 
longer timeframes to see the same efficiency and financial benefits. 
Using this model, improvements in productivity of 10% or 15% would break even at year 2 or 
year 1 respectively, leading to a net benefit of introduction of digital pathology. A department 
half the size of that described above would realise a profit after four years with a productivity 
improvement of 10%.  This cost-benefit analysis makes the assumption that all 
improvements in efficiency can be recouped as a financial benefit to the department. The 
validity of this assumption depends on the financial environment of the deployment, being 
easier to realise in health systems which pay for services on an item-by-item basis or in 
countries with the financial resources to pay for digital pathology.  
Alternatively, digital pathology could be seen as a cost in the context of the wider healthcare 
environment. A cost-benefit analyses by Ho et al (45) demonstrated a projected $18 million 
saving over a five-year period in an academic department processing 219,000 cases per 
year. The majority of these savings were estimated to arise from improvements in laboratory 
and pathologist efficiency, as a fully digital workflow would consolidate pathology 
departments spread over 20 institutions and reduce the number of internal and external 
consultations required.  The second element of cost savings was attributed to fewer 
episodes of under- or over-treatment by the subspecialisation of general pathologists 
facilitated by a digital pathology workflow. Both of these studies looked at a hypothetical 
implementation of digital pathology and there has yet to be a comprehensive analysis of the 
cost effectiveness of a fully digital workflow in routine clinical practice. 
 
Figure 4. Cost-benefit analysis of digital pathology. 
This line graph shows the cumulative cost or benefit over time of a full-scale digital pathology 
adoption, under varying conditions of productivity improvement. All lines start below zero due 
to the large initial setup costs of digital pathology. As benefits accumulate over time, the 
balance of cost and benefit increases toward the positive. The dips in the lines at 2021 
indicate the costs of an installation of a scanner upgrade, assuming this happens every 5 
years. With a 5% productivity improvement, the costs are never recouped. With a 10% 
productivity improvement, the costs are recouped by year 2 (2018). With a 15% productivity 
improvement, the costs are recouped by year 1 (2017). The model assumes all 
improvements in pathologist efficiency can be recouped as a financial gain.  
 
 
 
The regulatory environment 
Several federal or governmental bodies worldwide regulate the production and sale of 
medical devices. The US Food and Drug Administration, arguably the most influential 
regulator in the world, has previously considered digital slide scanners a class III medical 
device. These are considered to be a new technology, meaning that a rigorous clinical trial of 
validity must be submitted to obtain approval (so-called “pre-market approval” (PMA)), 
implying that full scale clinical trials to prove their safety are required (46). The FDA has 
proposed requirements for any trial of a whole slide imaging device (47). For example, rather 
than a standard comparison of glass and digital slides, the FDA has suggested that every 
slide in a trial also be reviewed by a third party, to validate the glass slide diagnosis itself (so 
correcting for inter- observer differences). This significantly increases the complexity and 
cost of a clinical trial. An initial lack of guidance from the FDA as to how digital slide 
scanners should be evaluated has recently been ameliorated by the publication of draft 
guidelines for technical assessment of this technology (48). 
  
Lack of regulatory approval is a very significant barrier in the USA (46), because without 
FDA approval digital slide scanners cannot be marketed or described as a medical 
diagnostic device. Whilst the FDA considers slide scanners to be a class III device, they 
have never been formally classified as such. Recent negotiations between the Digital 
Pathology Association and the FDA have resulted in advice that de novo applications are 
made for slide scanners to be used for primary diagnosis, and therefore classified as class II 
devices if the applications are successful (49). This pathway to approval is less complicated 
and more cost effective than the PMA route, and should a manufacturer be successful in 
obtaining a class II classification a precedent may be set for the use of digital slides in 
routine primary diagnostic practice.   Although the FDA (and MHRA in the UK) do not directly 
instruct doctors which technologies to use, without explicit regulatory approval doctors are 
likely to be reluctant to adopt digital pathology. In contrast, the granting of Health Canada 
class II licenses (50), and of a European CE mark (51) to certain digital pathology vendors 
has led to both of these regions starting to use digital slides for primary diagnosis. Although 
this in itself will not convince pathologists of the diagnostic validity of digital slides it is a step 
towards establishing validity on a worldwide scale. 
 
Acceptance by pathologists 
 
A pathologist viewing digital slides may defer to a glass slide for a number of reasons 
including unfamiliarity with the viewing software, network latency, a perceived inefficiency of 
digital diagnosis and a higher level of confidence with light microscope (LM) diagnosis. 
Deferral has been identified as a significant issue in some studies (52,53) and many 
pathologists feel that digital slides are too slow for routine diagnostic work. The design of a 
digital workstation is therefore of paramount importance in matching or surpassing the 
efficiency of LM diagnosis. 
 
Our group’s previous experimental comparison of the microscope and a conventional digital 
slide system found that digital slides were 67% less efficient than the microscope (54). 
Although these results were based on a small study (n = 4 pathologists) using a simple 
digital pathology workstation with a very small display (17 inches, 1024x768 pixels), they 
indicate that caution should be exercised in assuming that a digital slide viewer will be as 
fast as a microscope. It was concluded that most of the observed inefficiency was due to a 
combination of several factors including:  (i) the smaller field of view afforded by the digital 
slide system (ii) issues with the design of the software used for viewing the slides, and (iii) a 
lack of experience and training using digital slides with the participants. The first two of these 
issues were addressed in our subsequent work which found that using higher resolution 
displays and moving the image pixels more quickly could improve pathologist efficiency with 
digital slides to the point that time to diagnosis could be equivalent with the appropriate 
systems (55–57). Subsequent commercial digital pathology systems have placed greater 
emphasis on performance and usability. 
Practicing pathologists will be familiar with the variation in staining quality and intensity 
between laboratories and within their own institution. The digitisation of slides adds further 
potential variation in colour contrast and intensity, as each slide scanner will apply different 
image processing algorithms to the scanned slide. To address this, research groups have 
calibrated slide scanners using a phantom slide to represent a standardised spectrum of 
colour (58–60). One study (59) demonstrated an improvement in quantitative colour variation 
between multiple scanners from a single manufacturer when these scanners were calibrated 
with a phantom. However the calibration profile that gave the least quantitative variation in 
colour resulted in unrealistic production of colour when applied to tissue slides. More 
recently our group has evaluated a phantom calibration slide composed of a colour spectrum 
representative of H&E stained slides. Pathologists reported a higher diagnostic confidence 
when using calibrated slides (60). The growing interest in medical colour reproduction and 
standardisation has resulted in the establishment of a Medical Imaging Working Group by 
the International Consortium on Colour. A consensus statement in 2014 identified the 
development of colour calibration slides and work on colour calibration of medical image 
monitors as key priorities (61). 
The computer display on which slides are viewed is another important element of a digital 
pathology system. Two issues that arise when considering the performance of displays: 
colour calibration and screen resolution. Krupinski et al (62) showed no change in diagnostic 
accuracy when pathologists viewed snapshots breast cores on calibrated versus un-
calibrated displays but did note a faster time to diagnosis. Multiple groups have studied the 
effect of screen resolution with conflicting results. Intuitively one might expect that a large 
screen with greater resolution made digital diagnosis easier however Cucoranu et al (63) 
showed that a smaller, lower resolution monitor was associated with a greater confidence in 
identifying morphological features. Our work (64) showed no difference in time to diagnosis 
with increased monitor resolution. A higher resolution did result in a faster time to target, in 
this case identification of micrometastases in an axillary lymph node. Time to diagnosis was 
significantly faster using a light microscope than with either of the evaluated monitor 
configurations. These two studies compared different endpoints and studied three and nine 
pathologists respectively. It is unlikely that there is one screen resolution, configuration and 
calibration approach that will be best for all users and all specimens however further work is 
needed to identify the range of these parameters that offer the optimum experience of a 
digital pathology system. 
Only a few studies have directly addressed the issue of the acceptability of the technology to 
pathologists as a whole. In an early study, Dennis et al. surveyed 237 UK pathologists about 
their attitudes to telepathology (not digital slides). While there was broad approval for the use 
of telepathology for collaboration and case review at multidisciplinary team meetings, only a 
small minority reported that they would use telepathology for routine diagnosis of remote or 
local cases (11% and 9% respectively) (65). Furness et al. offered the option to view digital 
slides to 96 members of the UK renal quality assurance scheme. Only 26 of the members 
opted to view the digital slides. Those that did reported difficulties with using the slides, and 
with image quality (66). Other quality assurance schemes have subsequently mandated the 
use of digital slides with apparent success, for example the UK Bowel Cancer Screening 
Program (67). 
The transition from a glass slide to a fully digital department presents a considerable logistic 
and organisational challenge. Clearly this change can not happen instantaneously and a 
period of crossover would occur where a hybrid glass-digital system was in place. Many 
research groups have published their experience of and valuable lessons learned from this 
transition (19,42,68,69). Most recently Cheng et al detailed seven principles for 
implementation of a digital pathology department (68), namely: involvement of all laboratory 
staff, integration of IMS and LIS, workflow evaluation prior to implementation, proper training 
of all staff, rigorous validations studies, and robust governance processes. Critically the 
authors emphasize that these principles must be applied throughout and beyond the 
implementation process. The process took eight months, excluding an undefined pre-project 
to help plan the implementation timeline. 
Future directions and challenges 
Digital pathology has followed a classic early adoption curve  with use primarily in niche 
applications such as second opinion or frozen section diagnosis, MDT meetings and 
education. Following large scale validation studies and the development of efficient viewing 
systems, many more departments are investing in slide scanners and infrastructure to 
support digital pathology in routine clinical use.  Future innovations may include integration 
of radiology and histopathology images or the application of multi-stain imaging where 
multiple immunohistochemistry images can be over laid simultaneously. This would lead to a 
more efficient analysis of complex cases. Image analysis is beginning to generate useful 
prognostic data from H&E stained slides by analyzing metrics such as lymphocyte density, 
tumour stroma composition and nuclear morphometry and textural analysis. These 
approaches have been used in breast (70,71), colorectal (72) and ovarian (73) cancer case 
series. The routine use of molecular testing for mutation-specific treatments will add another 
layer of information to be integrated into a pathology report. It is uncertain how this 
information will be organized, integrated and visualized alongside traditional morphological 
and immunohistochemical data. The volume of data generated, and the relationships 
between these data present unique bioinformatics challenges. Being modular and flexible, 
the digital pathology workflow is well suited to rise to this challenge (74).  
 
Conclusions 
 
The digital slide is the most visible part of a digital pathology system. While this contains all 
the data needed for diagnosis to take place, a larger more comprehensive system is needed 
to ensure every step of the process runs smoothly and safely. Digital technologies can 
improve each stage of the diagnostic process, from accessioning of specimens and progress 
through the grossing/ cut up room to efficient viewing and software for annotation and report 
creation, and the ability to share slides inter- and intra- departmentally. Digital pathology 
offers the potential for improvements in quality, efficiency and safety that are compelling 
reasons for widespread implementation.  
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